Tampere University Hospital, department of Obstetrics and Gynecology, Tampere, Finland.
University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland.
Stem Cells Transl Med. 2018 Mar;7(3):295-304. doi: 10.1002/sctm.17-0208. Epub 2018 Jan 31.
Anal incontinence is a devastating condition that significantly reduces the quality of life. Our aim was to evaluate the effect of human adipose stem cell (hASC) injections in a rat model for anal sphincter injury, which is the main cause of anal incontinence in humans. Furthermore, we tested if the efficacy of hASCs could be improved by combining them with polyacrylamide hydrogel carrier, Bulkamid. Human ASCs derived from a female donor were culture expanded in DMEM/F12 supplemented with human platelet lysate. Female virgin Sprague-Dawley rats were randomized into four groups (n = 14-15/group): hASCs in saline or Bulkamid (3 × 10 /60 μl) and saline or Bulkamid without cells. Anorectal manometry (ARM) was performed before anal sphincter injury, at two (n = 58) and at four weeks after (n = 33). Additionally, the anal sphincter tissue was examined by micro-computed tomography (μCT) and the histological parameters were compared between the groups. The median resting and peak pressure during spontaneous contraction measured by ARM were significantly higher in hASC treatment groups compared with the control groups without hASCs. There was no statistical difference in functional results between the hASC-carrier groups (saline vs. Bulkamid). No difference was detected in the sphincter muscle continuation between the groups in the histology and μCT analysis. More inflammation was discovered in the group receiving saline with hASC. The hASC injection therapy with both saline and Bulkamid is a promising nonsurgical treatment for acute anal sphincter injury. Traditional histology combined with the 3D μCT image data lends greater confidence in assessing muscle healing and continuity. Stem Cells Translational Medicine 2018;7:295-304.
肛门失禁是一种严重影响生活质量的疾病。我们的目的是评估人脂肪干细胞(hASC)注射在大鼠肛门括约肌损伤模型中的效果,这是人类肛门失禁的主要原因。此外,我们还测试了将 hASC 与聚丙烯酰胺水凝胶载体 Bulkamid 联合使用是否可以提高其疗效。从一位女性供体中分离出的 hASC 在补充有人血小板裂解物的 DMEM/F12 中进行培养扩增。雌性处女 Sprague-Dawley 大鼠随机分为四组(每组 n=14-15):盐水或 Bulkamid(3×10 /60 μl)中的 hASC 和无细胞的盐水或 Bulkamid。在肛门括约肌损伤前、损伤后 2 周(n=58)和 4 周(n=33)进行肛门直肠测压(ARM)。此外,通过微计算机断层扫描(μCT)检查肛门括约肌组织,并比较各组之间的组织学参数。ARM 测量的自发性收缩时静息和峰值压力的中位数在 hASC 治疗组中明显高于无 hASC 的对照组。hASC-载体组(盐水与 Bulkamid)之间的功能结果无统计学差异。组织学和 μCT 分析均未发现各组之间的括约肌连续性存在差异。在接受 hASC 盐水治疗的组中发现更多的炎症。hASC 注射治疗盐水和 Bulkamid 均是急性肛门括约肌损伤的有前途的非手术治疗方法。传统组织学与 3D μCT 图像数据相结合,更有信心评估肌肉愈合和连续性。转化医学杂志 2018;7:295-304。